REDWOOD CITY, Calif., April 26, 2017 /PRNewswire/ -- ARMO BioSciences, Inc., a late-stage immuno-oncology company, today announced the appointment of Pierre Legault to its Board of Directors. Mr. Legault will serve as Chairman of the Audit Committee.
"Pierre is an experienced executive and board member who has extensive knowledge of the biotechnology and pharmaceutical industry and the finance function in both private and publically traded companies," said Peter Van Vlasselaer, Ph.D., President and Chief Executive Officer of ARMO. "We look forward to having Pierre lead our Audit Committee and believe his expertise will complement our board as ARMO continues to evolve into a later-stage immuno-oncology company."
Mr. Legault has over 25 years of executive leadership experience in the biopharmaceutical industry. Most recently, he served as Chief Executive Officer of NephroGenex from 2014 to 2016 and has served as Chairman of the Board since 2012. From 2010 to 2012, Mr. Legault was the Chief Executive officer of Prosidion. Previously, he was the Executive Vice President, Chief Financial Officer, and Treasurer of OSI Pharmaceuticals from 2009 to 2010. In addition, Mr. Legault was the Senior Executive Vice President and Chief Administrative Officer of Rite Aid Corporation and President of Eckerd Corporation. Earlier in his career, Mr. Legault worked for Sanofi-Aventis and predecessor companies over a 16 year period in several leadership positions, including President of Worldwide Dermatology Operations and Chief Financial Officer. Mr. Legault studied at McGill University, HEC Montreal and Harvard Business School. He holds an MBA, BAA, CA, CPA and Six Sigma Green Belt diplomas.
Mr. Legault also serves as a member of the board of directors at Poxel, Syndax, and Iroko Pharmaceuticals.
About ARMO BioSciences
ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary products that activate the immune system of cancer patients to recognize and eradicate tumors. The Company's lead product candidate, AM0010, stimulates the survival, expansion and killing (cytotoxic) potential of a particular type of white blood cell in the immune system called CD8+ T cells. CD8+ T cells recognize and kill cancer cells and an increased presence of intra-tumoral CD8+ T cells may result in improved prognosis and survival in patients.
In addition, ARMO is developing a robust immuno-oncology pipeline that includes validated product candidates aimed at treating a variety of cancers in combination with standard of care treatments and emerging immunotherapies.
For more information, please visit www.armobio.com.
SOURCE ARMO BioSciences, Inc.